Welcome to our dedicated page for Kazia Therapeuti SEC filings (Ticker: KZIA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kazia Therapeutics Limited filings document foreign private issuer disclosures for a clinical-stage oncology company with Nasdaq-traded American depositary shares. Form 6-K reports furnish investor presentations, fact sheets, clinical updates for paxalisib, material-event disclosures, operating and financial results, and updates related to the company's oncology pipeline.
The filing record also covers capital structure and financing activity, including ADS sales agreements, registration-statement references, private placements, ordinary shares, pre-funded warrants, and placement-agent warrants. Governance disclosures include annual general meeting results, director and committee changes, and shareholder voting matters. Material-agreement filings describe licensing arrangements such as the SETDB1-targeted epigenetic platform, while risk and forward-looking disclosures address development-stage biotechnology, regulatory plans, clinical programs, and capital-market compliance.
Kazia Therapeutics Limited files a prospectus supplement registering 266,666 American Depositary Shares representing 133,333,000 Ordinary Shares as part of its existing registration. The supplement attaches a Form 6-K disclosing an expansion of the ongoing Phase 1b paxalisib trial in advanced triple negative breast cancer, increasing planned enrollment from 12 to 36 patients. The ADSs trade on Nasdaq under the symbol KZIA; the last reported sale price was $13.66 per ADS on May 22, 2026.
Kazia Therapeutics is expanding its ongoing Phase 1b trial of lead drug paxalisib in advanced triple negative breast cancer. Planned enrollment will rise from 12 to 36 patients after continued encouraging safety, tolerability and early clinical activity in combination with pembrolizumab and chemotherapy.
The larger study is intended to refine dosing and better assess early measures of benefit such as objective response rate, progression-free survival and translational biomarkers. Kazia highlights preclinical data supporting dual PI3K/mTOR inhibition in TNBC and notes that additional clinical updates are anticipated throughout 2026 and into 2027.
Kazia Therapeutics Ltd filed an initial Form 3 for Sudha Rao
Kazia Therapeutics Limited has furnished an investor presentation and fact sheet highlighting its oncology pipeline and financial position. The company reports cash and cash equivalents of about US$46 million, no outstanding debt, and expects this to fund planned operations into 2029, excluding any additional or expanded trials. Kazia’s lead asset is paxalisib, a brain‑penetrant dual PI3K/mTOR inhibitor being studied in glioblastoma, breast cancer, childhood brain cancers, and brain metastases. Earlier‑stage programs include the PD‑L1 degrader NDL2, the SETDB1 inhibitor MSETC, and VEGFR3 inhibitor EVT801. The materials also describe a $50 million private placement of equity securities in Q4 2025 and list anticipated milestones in 2026, including FDA discussions on paxalisib in GBM, IND‑enabling work for NDL2 and MSETC, and multiple clinical readouts.
Kazia Therapeutics Limited is supplementing its prospectus to register 232,956 American Depositary Shares representing 116,478,000 Ordinary Shares. The supplement incorporates a Form 6-K disclosing the appointment of Dr. Sudha Rao as Chief Scientific Officer, effective April 13, 2026.
Dr. Rao will serve part-time (three days per week) with a base salary of AUD$325,000, a target annual bonus of 40%, and a proposed grant of 250,000 ADS options (one-third vest at commencement, remainder in two equal annual installments). The employment agreement permits concurrent work with QIMR Berghofer Medical Research Institute.
Kazia Therapeutics Limited files a prospectus supplement registering 95,110 American Depositary Shares (ADS) representing 47,555,000 Ordinary Shares. The supplement incorporates a Form 6-K reporting the appointment of Dr. Sudha Rao as Chief Scientific Officer, effective April 13, 2026, and summarizes her employment terms.
The Form 6-K discloses Dr. Rao’s part‑time (three days/week) role with an annual base salary of AUD$325,000, a target annual performance bonus of 40% of base salary, and a proposed grant of 250,000 ADS options (subject to Board approval) with staggered vesting. The ADSs trade on Nasdaq under the symbol KZIA (last reported sale price $9.46 per ADS as of April 14, 2026).
Kazia Therapeutics Limited files a prospectus supplement registering 10,700,211 American Depositary Shares (ADS), representing 5,350,105,500 ordinary shares, and incorporates a Form 6-K dated April 15, 2026 into that prospectus supplement. The supplement updates the Prospectus dated December 23, 2025 and includes a Form 6-K disclosing the appointment of Dr. Sudha Rao as Chief Scientific Officer, effective April 13, 2026.
Under an employment agreement, Dr. Rao will work part-time (three days per week) with an annual base salary of AUD$325,000, a target annual performance bonus of 40% of base salary, and a proposed grant of 250,000 ADS options subject to approval by the Company’s Board of Directors, with one-third vesting at commencement and the remainder vesting in two equal annual installments.
Kazia Therapeutics filed a prospectus supplement and Form 6-K updating its Registration Statement and furnishing a press release announcing the appointment of Dr. Sudha Rao as Chief Scientific Officer, effective April 13, 2026. The supplement states 266,666 American Depositary Shares representing 133,333,000 Ordinary Shares. The Form 6-K describes Dr. Rao’s part-time employment (three days per week), an annual base salary of AUD$325,000, a target annual performance bonus of 40% of base salary, and a proposed grant of 250,000 ADS options (subject to Board approval) with one-third vesting on commencement and the remainder vesting in two equal annual installments.
Kazia Therapeutics Limited has appointed Dr. Sudha Rao as Chief Scientific Officer under a new employment agreement. Effective April 13, 2026, she will serve part-time, three days per week, with an annual base salary of AUD$325,000 and a target annual bonus equal to 40% of base salary.
The agreement includes options to acquire 250,000 American Depositary Shares, with one-third vesting at commencement and the remainder vesting in equal tranches on the first and second anniversaries, subject to board approval. Dr. Rao will continue her role at QIMR Berghofer Medical Research Institute while leading Kazia’s scientific and R&D strategy.
Kazia Therapeutics Limited is registering 232,956 American Depositary Shares (ADSs) representing 116,478,000 Ordinary Shares under a prospectus supplement dated April 13, 2026. The company disclosed it entered a license and commercialisation agreement with QIMR Berghofer on April 10, 2026, under which Kazia obtained an exclusive worldwide license to a SETDB1-targeted epigenetic platform.
The agreement requires an upfront license payment of $1,390,000 payable within 15 business days of execution and a tiered revenue-sharing arrangement on commercialization revenue. The licensed program is in preclinical development; Kazia estimates combined costs of about $6 million over 18 months to advance the SETDB1 and PD-L1 degrader programs to IND readiness.